Mary Allen

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention
    Mary Allen
    National Institutes of Health, Bethesda, MD 20817, USA
    Soc Sci Med 66:945-51. 2008
  2. ncbi request reprint Current advances and challenges in HIV-1 vaccines
    Isaac R Rodriguez-Chavez
    Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Curr HIV/AIDS Rep 3:39-47. 2006
  3. ncbi request reprint Current advances in HIV vaccines
    M Patricia D'Souza
    Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 6700B Rockledge Drive, Room 5127, Bethesda, MD 20892, USA
    Curr HIV/AIDS Rep 1:18-24. 2004
  4. ncbi request reprint Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120
    Farley Cleghorn
    Center for HIV AIDS, Constella Futures, Washington, DC, USA
    J Acquir Immune Defic Syndr 46:222-30. 2007
  5. ncbi request reprint Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients
    Marta Louise Ackers
    HIV Vaccine Section, Epidemiology Branch, Division of HIV AIDS Prevention Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Infect Dis 187:879-86. 2003
  6. ncbi request reprint High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects
    Paul A Goepfert
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
    J Infect Dis 192:1249-59. 2005

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention
    Mary Allen
    National Institutes of Health, Bethesda, MD 20817, USA
    Soc Sci Med 66:945-51. 2008
    ..Although further research is necessary, this model could be adapted for use in different clinical trials...
  2. ncbi request reprint Current advances and challenges in HIV-1 vaccines
    Isaac R Rodriguez-Chavez
    Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Curr HIV/AIDS Rep 3:39-47. 2006
    ..Simultaneously, expanded efforts continue to identify new designs that induce mucosal immunity as well as broadly neutralizing antibodies...
  3. ncbi request reprint Current advances in HIV vaccines
    M Patricia D'Souza
    Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 6700B Rockledge Drive, Room 5127, Bethesda, MD 20892, USA
    Curr HIV/AIDS Rep 1:18-24. 2004
    ..One or more candidate vaccines will likely advance into efficacy trials within the next few years, while efforts to identify new designs that induce broadly neutralizing antibodies continue with incremental success...
  4. ncbi request reprint Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120
    Farley Cleghorn
    Center for HIV AIDS, Constella Futures, Washington, DC, USA
    J Acquir Immune Defic Syndr 46:222-30. 2007
    ..vCP1452 was administered alone or with a heterologous boost of MN rgp120 glycoprotein. The trial was pivotal in deciding whether these vaccines advanced to phase 3 efficacy trials...
  5. ncbi request reprint Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients
    Marta Louise Ackers
    HIV Vaccine Section, Epidemiology Branch, Division of HIV AIDS Prevention Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Infect Dis 187:879-86. 2003
    ..The potential for vaccine recipients being misclassified as HIV infected increased with vaccine complexity...
  6. ncbi request reprint High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects
    Paul A Goepfert
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
    J Infect Dis 192:1249-59. 2005
    ..0) TCID50 (60 participants) than when given at the regular dose, 10(7.26) TCID50 (40 participants); as a control, a placebo vaccine preparation also was administered (10 participants)...